Warning: Illegal string offset 'enable' in /home/redhothe/public_html/wp-content/plugins/conditional-widgets/logic.php on line 171
RED HOT Contributors

 

STAT Plus: Bristol scrambles to push Celgene deal, but are the odds as high as some think?

0
CREDIT: This post was originally published on this site

Bristol-Myers Squibb (BMY) management last Friday called a meeting with Wall Street analysts in what one described as a “semi-urgent fashion” in hopes of convincing investors that its $74 billion bid for Celgene (CELG) really is a good deal. But even after the session, Tim Anderson of Wolfe Research signaled that the odds the transaction will close are “not as high as some are thinking.”

The move came a week after two funds opposed the proposal, arguing Bristol stockholders are being asked to accept too much risk, because the transaction is priced “well below” asset value, and “could be more difficult to achieve than depicted” by Bristol management. The funds, Wellington Management and Starboard Value, openly expressed concerns that were already building among some investors.

Continue to STAT Plus to read the full story…

Avatar

About

We Support OUR Contributors

Comments are closed.

Get Our Newsletter

 Receive podcast updates
Exclusive insights
Patient Engagement Tips from industry experts
We hate SPAM as much as you do and promise to keep your email address safe.
  • Subscribe to the Podcast